Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kiniksa Pharmaceuticals International, plc as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 224
- +24 vs. Q3 2025
- Shares held
- 43.0M
- +2.55M (+6.3%) vs. Q3 2025
- Total value
- $1.77B
- +$202.9M (+12.9%) vs. Q3 2025
- New holders
- 42
- 79 more added
- Sold out
- 18
- 70 more reduced
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KNSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 267 | $2.99B |
| Q1 2026 | 228 | $2.18B |
| Q4 2025 | 224 | $1.77B |
| Q3 2025 | 204 | $1.59B |
| Q2 2025 | 189 | $1.10B |
| Q1 2025 | 176 | $889.4M |
| Q4 2024 | 160 | $773.1M |
| Q3 2024 | 176 | $991.2M |
| Q2 2024 | 133 | $659.4M |
| Q1 2024 | 154 | $768.1M |
| Q4 2023 | 142 | $600.4M |
| Q3 2023 | 134 | $605.8M |
| Q2 2023 | 127 | $447.7M |
| Q1 2023 | 132 | $339.6M |
| Q4 2022 | 125 | $450.0M |
| Q3 2022 | 104 | $383.2M |
| Q2 2022 | 92 | $290.5M |
| Q1 2022 | 96 | $306.0M |
| Q4 2021 | 103 | $346.4M |
| Q3 2021 | 101 | $332.0M |
| Q2 2021 | 102 | $402.0M |
| Q1 2021 | 105 | $537.6M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kiniksa Pharmaceuticals International, plc; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 587,000 | $24.2M | 1.03% | +437,000+291.3% | Added |
| Rice Hall James & Associates, LLC | 596,431 | $24.6M | 1.35% | +18,609+3.2% | Added |
| Deutsche Bank AG | 630,291 | $26.0M | 0.01% | +96,916+18.2% | Added |
| Driehaus Capital Management LLC | 632,827 | $26.1M | 0.18% | −21,758−3.3% | Reduced |
| Parkman Healthcare Partners LLC | 665,208 | $27.4M | 2.61% | −6,384−1.0% | Reduced |
| Dimensional Fund Advisors LP | 683,505 | $28.2M | 0.01% | +51,382+8.1% | Added |
| Connor, Clark & Lunn Investment Management Ltd. | 739,326 | $30.5M | 0.08% | +13,971+1.9% | Added |
| Citadel Advisors LLC | 742,118 | $30.6M | 0.02% | +427,562+135.9% | Added |
| Qube Research & Technologies Ltd | 766,291 | $31.6M | 0.05% | +76,403+11.1% | Added |
| Pictet Asset Management Holding SA | 787,520 | $32.5M | 0.03% | −144,576−15.5% | Reduced |
| Point72 Asset Management, L.P. | 797,137 | $32.9M | 0.05% | +230,210+40.6% | Added |
| Millennium Management LLC | 825,285 | $34.0M | 0.02% | −188,840−18.6% | Reduced |
| Goldman Sachs Group Inc | 829,417 | $34.2M | 0.00% | +282,907+51.8% | Added |
| BNP Paribas Arbitrage, SA | 831,777 | $34.3M | 0.02% | +178,366+27.3% | Added |
| Arrowstreet Capital, Limited Partnership | 1,068,216 | $44.1M | 0.03% | −470.0% | Reduced |
| D. E. Shaw & Co., Inc. | 1,241,621 | $51.2M | 0.04% | +107,435+9.5% | Added |
| Fairmount Funds Management LLC | 1,319,688 | $54.4M | 4.14% | −453,151−25.6% | Reduced |
| Morgan Stanley | 1,360,044 | $56.1M | 0.00% | −2,879−0.2% | Reduced |
| FMR LLC | 1,642,863 | $67.8M | 0.00% | +843,108+105.4% | Added |
| Acadian Asset Management LLC | 1,713,043 | $70.6M | 0.12% | +94,522+5.8% | Added |
| Tang Capital Management LLC | 2,259,889 | $93.2M | 4.60% | −68,720−3.0% | Reduced |
| Baker Bros. Advisors LP | 2,826,246 | $116.6M | 0.68% | +1,577+0.1% | Added |
| Vanguard Group Inc | 3,112,937 | $128.4M | 0.00% | +49,802+1.6% | Added |
| Rubric Capital Management LP | 3,328,653 | $137.3M | 1.64% | −671,347−16.8% | Reduced |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −88,910−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −59,000−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −43,346−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −35,847−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −30,389−100.0% | Sold out |
| Birchview Capital, LP | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Lion Point Capital, LP | 0 | $0 | 0.00% | −23,400−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −19,777−100.0% | Sold out |
| Prosperity Wealth Management, Inc. | 0 | $0 | 0.00% | −13,900−100.0% | Sold out |
| Kingsview Wealth Management, LLC | 0 | $0 | 0.00% | −9,941−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −9,040−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −8,100−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −8,080−100.0% | Sold out |
| PharVision Advisers, LLC | 0 | $0 | 0.00% | −6,722−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −5,854−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −5,800−100.0% | Sold out |
| Marquette Asset Management, LLC | 0 | $0 | 0.00% | −61−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Sheets Smith Investment Management | – | – | – | – | Not filed |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |
| Bryce Point Capital, LLC | – | – | – | – | Not filed |